Mucopolysaccharidosis VI Clinical Trial
Official title:
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Verified date | December 2022 |
Source | Hospital de Clinicas de Porto Alegre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.
Status | Active, not recruiting |
Enrollment | 10 |
Est. completion date | August 3, 2023 |
Est. primary completion date | May 4, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 40 Years |
Eligibility | Inclusion Criteria: - Confirmed biochemical or molecular diagnosis of MPS VI or MPS IVA. - Age between 10 and 40 years. - Presence of aortic root diameter greater than 1.0 standard deviation, as determined by local measurement. - Be in a stable treatment regime in the last 3 months (without performing Enzyme replacement therapy (ERT), or performing ERT on a regular basis). - Patient who agree to participate in the study protocol by signing a free informed consent form. Exclusion Criteria: - Patient who underwent previous aortic surgery. - Patient with aortic root diameter greater than 5 cm. - Patient on angiotensin-converting-enzyme (ACE) inhibitor. In case of use of beta-blocker, or calcium channel blocker, patient without adequate control of blood pressure in the last 3 months. - Patients with previous adverse events related to treatment with losartan or contraindication to this treatment. - Inability, in the opinion of the investigator, to complete the study procedures. |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital de Clinicas de Porto Alegre | Porto Alegre | Rio Grande Do Sul |
Lead Sponsor | Collaborator |
---|---|
Hospital de Clinicas de Porto Alegre | The Isaac Foundation |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Glycosaminoglycan after 6 months | Difference in urinary glycosaminoglycan levels after 6 months | 6 months | |
Other | Glycosaminoglycan after 12 months | Difference in urinary glycosaminoglycan levels after 12 months | 12 months | |
Primary | Adverse events related to losartan use | The frequency of adverse events after 12 months will be compared among the groups | 12 months | |
Secondary | Z score of maximal aortic root diameter measured by Valsalva sinus | Reduction over time in the Z score of maximal aortic root diameter measured by Valsalva sinus echocardiogram between the baseline assessment and 12 months after treatment with losartan. | 12 months | |
Secondary | Changes of serum levels of transforming growth factor (TGF-Beta-1) | Changes of serum levels of transforming growth factor (TGF-Beta-1) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of brain-type natriuretic peptide (BNP) | Changes of serum levels of brain-type natriuretic peptide between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of N-terminal pro b-type natriuretic peptide (NT-ProBNP) | Changes of serum levels of N-terminal pro b-type natriuretic (NT-ProBNP) peptide between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of creatine kinase-myocardial ban (ck-mb) | Changes of serum levels of creatine kinase-myocardial ban (ck-mb) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6) | Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16) | Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Endocan-1 (ESM-1) | Changes of serum levels of Endocan-1 (ESM-1) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Placental growth factor (PLGF) | Changes of serum levels ofPlacental growth factor (PLGF) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Fatty acid binding protein 3 (FAPB3) | Changes of serum levels of Fatty acid binding protein 3 (FAPB3) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Fatty acid binding protein 4 (FAPB4) | Changes of serum levels of Fatty acid binding protein 4 (FAPB4) between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Oncostatin M | Changes of serum levels of Oncostatin M between baseline and 12 months | 12 months | |
Secondary | Changes of serum levels of Troponin I | Changes of serum levels of Troponin I between baseline and 12 months | 12 months | |
Secondary | Changes of ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months. | Reduction over time in the ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months. | 12 months | |
Secondary | Changes in mitral valve regurgitation | Alteration of the parameter of mitral valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months. | 12 months | |
Secondary | Changes in aortic valve regurgitation | Alteration of the parameter of aortic valve regurgitation as assessed by a semi-quantitative echocardiographic method between the baseline and 12 months. | 12 months | |
Secondary | Changes in ejection fraction | Alteration of the ejection fraction measurement as assessed by echocardiography between the baseline and 12 months. | 12 months | |
Secondary | Changes in left ventricular longitudinal strain | Alteration of the measurement of left ventricular longitudinal strain as assessed by echocardiography between the baseline and 12 months. | 12 months | |
Secondary | Changes in E/A ratio | Alteration of the parameter E/A ratio as assessed by echocardiography between the baseline and 12 months . | 12 months | |
Secondary | Changes in E/e' ratio | Alteration of the parameter E/e' ratio as assessed by echocardiography between the baseline and 12 months. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01675674 -
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
|
N/A | |
Completed |
NCT00067470 -
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
|
Phase 3 | |
Completed |
NCT00048620 -
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
|
Phase 1 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT01707433 -
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
|
N/A | |
Terminated |
NCT00748969 -
Clinical Trial of Growth Hormone in MPS I, II, and VI
|
Phase 2/Phase 3 | |
Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
Completed |
NCT00299000 -
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
|
Phase 4 | |
Completed |
NCT00176917 -
Stem Cell Transplantation for Hurler
|
Phase 2 | |
Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
Completed |
NCT00048711 -
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
|
Phase 2 | |
Active, not recruiting |
NCT03153319 -
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
|
Phase 1/Phase 2 | |
Completed |
NCT00104234 -
Study of rhASB in Patients With Mucopolysaccharidosis VI
|
Phase 3 | |
Completed |
NCT03370653 -
A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
|
Phase 2 | |
Recruiting |
NCT06036693 -
MPS (RaDiCo Cohort) (RaDiCo-MPS)
|
||
Active, not recruiting |
NCT00005900 -
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01586455 -
Human Placental-Derived Stem Cell Transplantation
|
Phase 1 |